BioSpace News Archive

Sierra Oncology, Inc. reported its financial and operational results for the first quarter ended March 31, 2019.

Companies to Pursue a Human Genetics Approach to Drug Discovery and Development

Bristol-Myers Squibb Company announced that it priced its previously announced private offering of senior unsecured notes in a combined aggregate principal amount of $19 billion.

Rare Diseases: New development candidate announced for glycogen storage disease type 1a (GSD1a), a rare metabolic disorder; Company now has five rare disease programs in its pipeline

BioNTech SE announced the acquisition of antibody assets and infrastructure from San Diego-based MabVax Therapeutics Holding, Inc., a clinical-stage oncology drug development company.

ITM Isotopen Technologien München AG announced the lease of a new building in Neufahrn near Munich to increase the production capacity of no-carrier-added Lutetium-177 and high-purity Lutetium-177 containing radiopharmaceuticals.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as an R&D pipeline of medications targeting diseases with high unmet medical needs, will report financial results for the three months ended March 31, 2019,

Vitamin Angels is thrilled to be a recipient of its 8th 4-star rating, the highest value score available, from Charity Navigator, the nation’s premier charity evaluator.

Stellar Biotechnologies, Inc. reported financial results for the three and six months ended March 31, 2019 and provided an update on its business.

United Imaging Healthcare (UIH), an international leader in advanced medical imaging and radiotherapy equipment, announced the U.S. Food and Drug Administration (FDA) clearance of the uPMR 790 HD TOF PET/MR.